Analysis puts tirzepatide at nearly two-thirds of Lilly's quarterly revenue

Eli Lilly's tirzepatide medicines, sold as Mounjaro for type 2 diabetes and Zepbound for weight loss, now account for close to two-thirds of the company's quarterly revenue, according to a pipeline analysis published this week ^[1]. The finding underscores just how central these two products have become to Lilly's business, and how much of the company's future depends on them.

The same analysis notes that this incretin revenue is funding an expanding pipeline, including the recently approved oral GLP-1 drug Foundayo (orforglipron) and the experimental triple-hormone drug retatrutide ^[1]. Lilly is reportedly planning to file for US approval of retatrutide in the first quarter of 2027 ^[1].

The report frames this as a shift from a year ago, when Lilly's pipeline strategy looked different, though the specifics of that earlier strategy were not detailed in the portion of the analysis available ^[1]. What is clear from the source is that tirzepatide's commercial success is now the financial engine behind Lilly's next generation of metabolic drugs ^[1].

Beyond the revenue figure and the retatrutide filing timeline, the source does not provide additional numbers, such as exact dollar amounts, growth rates, or details on Foundayo's current sales performance ^[1]. Those specifics are not yet known from the available reporting.

Why it matters for patients

For people currently taking Mounjaro or Zepbound, or considering starting one of these tirzepatide medicines, this analysis is mostly a signal about the company behind the drugs rather than about the drugs themselves. When a medicine generates a large share of a manufacturer's revenue, that company typically has strong incentives to keep supply steady, invest in manufacturing capacity, and continue running long-term safety studies ^[1].

The fact that tirzepatide profits are funding newer drugs like Foundayo and retatrutide also matters for patients who might switch treatments in the future. Foundayo is already approved as an oral GLP-1 option, meaning patients who prefer a pill over an injection now have that choice on the market ^[1]. Retatrutide, which is still investigational, targets three hormone pathways instead of the two that tirzepatide affects, and its planned 2027 US filing suggests patients may eventually have another option, though it is not yet approved and its safety and effectiveness profile compared to existing drugs is not established in the source material ^[1].

Patients should also understand that a company's financial concentration in one drug class carries some risk. If competition, pricing pressure, or new safety findings affected tirzepatide sales, that could ripple into how much Lilly can invest in supply and research for its other products ^[1]. The source does not address these risks directly, but the revenue concentration itself highlights how much rides on tirzepatide's continued market performance.

What happens next

The next concrete milestone flagged in the source is Lilly's planned US regulatory filing for retatrutide, expected in the first quarter of 2027 ^[1]. Until then, patients and clinicians will not have official government review of retatrutide's safety and effectiveness data. No specific dates were given for further tirzepatide supply updates or additional Foundayo developments in the available reporting ^[1].